Axsome announces positive outcome of interim analysis of ADVANCE-1 Phase 2/3 trial
Axsome announced a positive outcome of the interim analysis for the ADVANCE-1 Phase 2/3 trial of AXS-05 in agitation associated with Alzheimer’s disease. Based on the results of the analysis, the IDMC recommended continuation of the AXS-05 treatment arm. December 10, 2018